全文获取类型
收费全文 | 3205258篇 |
免费 | 262120篇 |
国内免费 | 9314篇 |
专业分类
耳鼻咽喉 | 45262篇 |
儿科学 | 100867篇 |
妇产科学 | 86434篇 |
基础医学 | 446400篇 |
口腔科学 | 91965篇 |
临床医学 | 293472篇 |
内科学 | 634665篇 |
皮肤病学 | 69684篇 |
神经病学 | 269567篇 |
特种医学 | 128992篇 |
外国民族医学 | 1111篇 |
外科学 | 489502篇 |
综合类 | 76904篇 |
现状与发展 | 3篇 |
一般理论 | 1298篇 |
预防医学 | 262230篇 |
眼科学 | 73599篇 |
药学 | 233601篇 |
9篇 | |
中国医学 | 5769篇 |
肿瘤学 | 165358篇 |
出版年
2018年 | 32851篇 |
2016年 | 29192篇 |
2015年 | 32872篇 |
2014年 | 46819篇 |
2013年 | 71046篇 |
2012年 | 92190篇 |
2011年 | 98196篇 |
2010年 | 59244篇 |
2009年 | 57106篇 |
2008年 | 92718篇 |
2007年 | 98754篇 |
2006年 | 99861篇 |
2005年 | 97289篇 |
2004年 | 93371篇 |
2003年 | 90460篇 |
2002年 | 88082篇 |
2001年 | 147384篇 |
2000年 | 152368篇 |
1999年 | 128296篇 |
1998年 | 38624篇 |
1997年 | 34844篇 |
1996年 | 35158篇 |
1995年 | 34628篇 |
1994年 | 32459篇 |
1993年 | 30390篇 |
1992年 | 104889篇 |
1991年 | 101663篇 |
1990年 | 98086篇 |
1989年 | 93967篇 |
1988年 | 87445篇 |
1987年 | 86237篇 |
1986年 | 81616篇 |
1985年 | 78437篇 |
1984年 | 59778篇 |
1983年 | 50941篇 |
1982年 | 31499篇 |
1981年 | 28334篇 |
1980年 | 26660篇 |
1979年 | 55680篇 |
1978年 | 39816篇 |
1977年 | 33536篇 |
1976年 | 31335篇 |
1975年 | 32895篇 |
1974年 | 40084篇 |
1973年 | 38178篇 |
1972年 | 35707篇 |
1971年 | 33084篇 |
1970年 | 30916篇 |
1969年 | 28786篇 |
1968年 | 26480篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
S. Vitko Z. Wlodarczyk L. Kyllönen Z. Czajkowski R. Margreiter L. Backman F. Perner P. Rigotti B. Jaques D. Abramowicz M. Kessler J. Sanchez-Plumed L. Rostaing R.S. Rodger D. Donati Y. Vanrenterghem 《American journal of transplantation》2006,6(3):531-538
Tacrolimus combined with mycophenolate mofetil (MMF) is an effective regimen in kidney transplantation. This study compared the efficacy of combining tacrolimus and two different dosages of sirolimus with an established tacrolimus-MMF regimen. Each day in addition to tacrolimus, 325 patients received 2 mg sirolimus (TAC-SRL2 mg), 325 patients received 0.5 mg sirolimus (TAC-SRL0.5 mg) and 327 patients 1 g MMF (TAC-MMF). The initial tacrolimus dose was 0.2 mg/kg/day. Sirolimus patients received loading doses of 6 or 1.5 mg, and daily doses of 2 or 0.5 mg thereafter. Steroid administration was identical for all groups. The incidence of biopsy-proven acute rejection was lower in the TAC-SRL2 mg group (15.7%) compared with the TAC-SRL0.5 mg (25.2%, p = 0.003) and the TAC-MMF groups (22.3%, p = 0.036). Six-month graft survival was 91.0% (TAC-SRL2 mg), 92.6% (TAC-SRL0.5 mg) and 92.4% (TAC-MMF); the respective values for patient survival were 98.1%, 97.8% and 97.9%. Thirty-four patients (10.5%), 19 patients (5.8%) and 16 patients (4.9%) in the TAC-SRL2 mg, TAC-SRL0.5 mg and TAC-MMF groups, respectively, discontinued the study because of adverse events. Hyperlipemia was reported more often in the TAC-SRL2 mg group (24.0%) compared with 19.4% (TAC-SRL0.5 mg) and 11.0% (TAC-MMF; p < 0.05). Combining 2 mg sirolimus/day with tacrolimus results in lower rates of acute rejection, but a higher incidence of adverse events. 相似文献
992.
993.
994.
P F Plouin D L Clement H Boccalon J Dormandy I Durand-Zaleski G Fowkes L Norgren T Brown 《International angiology》2003,22(4):333-339
Atherosclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function or preventing clinical events are only in the early recruitment phase. Revascularization should be undertaken in patients with ARAS and resistant hypertension or heart failure, and probably in those with rapidly deteriorating renal function or with an increase in plasma creatinine levels during angiotensin-converting enzyme inhibition. With or without revascularization, medical therapy using antihypertensive, hypolipidemic and antiplatelet agents is necessary in almost all cases. 相似文献
995.
996.
997.
998.
999.
1000.